BioNTech SE (NASDAQ: BNTX) shares surged 7.80% in pre-market trading on Monday, June 2, 2025, following the news of Moderna's FDA approval for its latest COVID-19 vaccine. The positive sentiment in the vaccine sector appears to be boosting BioNTech's stock, as investors anticipate potential increased demand for COVID-19 vaccines.
Over the weekend, Moderna announced that the U.S. Food and Drug Administration (FDA) had approved its mNEXSPIKE COVID-19 vaccine for use in adults aged 65 and above, as well as individuals between 12 and 64 years old with high-risk conditions. This approval comes amid reports of rising COVID-19 cases in several Asian countries, including Thailand, Hong Kong, Malaysia, and Singapore, driven by new variants such as XEC and subvariants of JN.1.
While BioNTech has not made any specific announcements, the market reaction suggests that investors are optimistic about the potential for increased vaccine sales. As a key player in the COVID-19 vaccine market through its partnership with Pfizer, BioNTech could benefit from any renewed focus on vaccination efforts. The company may also be working on updated vaccines to address emerging variants, although no official statements have been made to this effect.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.